Abstract TH303: Uncontrolled Hypertension in a Young Adult With Thrombotic Microangiopathy: Cause, Consequence, or Both?
Hypertension · 2026-10 · 83 (Suppl_1)
DOI: 10.1161/hyp.83.suppl_1.th303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hypertension, 2026-10. Verfasst von Ahmed Diab und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Case presentation: A 39-year-old man with no known medical history presented with one month of progressive headache, exertional and rest dyspnea, nausea, and vomiting. Blood pressure was 218/163 mmHg and he required supplemental oxygen. Chest radiograph showed pulmonary edema; ECG showed left ventricular (LV) hypertrophy with lateral T-wave inversions. Creatinine was 8.9 mg/dL (baseline 0.9), hemoglobin 11.3 g/dL, platelets 119 K/uL, haptoglobin under 10, lactate dehydrogenase 749 units/L, with reticulocytosis and schistocytes on smear. Urinalysis showed proteinuria and hematuria. Echocardiography showed a severely dilated LV, ejection fraction (EF) 31 percent, and global hypokinesis. Differential Diagnosis: Microangiopathic hemolytic anemia, thrombocytopenia, and AKI raised concern for thrombotic microangiopathy (TMA). Despite an intermediate PLASMIC score of 5, thrombotic thrombocytopenic purpura (TTP) was less likely given severe renal failure, and ADAMTS13 returned at 27 percent, above the severe-deficiency threshold. Complement, autoimmune, infectious, and paraprotein workup were unrevealing; endocrine testing and renal artery imaging were normal aside from a small adrenal adenoma. Kidney biopsy showed active TMA with fibrin thrombi and entrapped red cells in non-sclerotic glomeruli, alongside arteriosclerosis, interstitial fibrosis, and global glomerulosclerosis in 4 of 8 glomeruli. Genetic testing identified variants of uncertain significance in complement-pathway genes, including CFH p.Ser884Tyr (linked to atypical hemolytic uremic syndrome and C3 glomerulopathy), a novel THBD in-frame duplication, and heterozygous loss of CFHR3-CFHR1, suggesting possible complement-mediated susceptibility. Treatment and Management: Blood pressure was lowered with intravenous labetalol and oral hydralazine, then transitioned to oral therapy with diuresis. Plasma exchange was deferred once TTP was excluded. Eculizumab was deferred by insurance and is being pursued outpatient. Outcome and Follow-Up: Hemolysis and thrombocytopenia improved with blood pressure control, supporting hypertension-associated TMA as a major contributor. Renal function did not recover and hemodialysis was initiated. LVEF improved to 48 percent. Teaching Points: Malignant hypertension can drive a secondary TMA, but hypertension can equally be a consequence of renal TMA, and the two may coexist. Concurrent processes should be considered when systemic hemolysis improves with blood pressure control, but renal injury persists. Fibrin thrombi in non-sclerotic glomeruli support active glomerular disease but do not distinguish complement-mediated from hypertension-associated TMA, supporting genetic testing when the clinical course is discordant.
Zitieren
APA
Diab, A., Shammas, N., & Mahmoud, A. (2026). Abstract TH303: Uncontrolled Hypertension in a Young Adult With Thrombotic Microangiopathy: Cause, Consequence, or Both?. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.th303
Vancouver
Diab A, Shammas N, Mahmoud A. Abstract TH303: Uncontrolled Hypertension in a Young Adult With Thrombotic Microangiopathy: Cause, Consequence, or Both?. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.th303
BibTeX
@article{Diab2026,
author = {Diab, Ahmed and Shammas, Nicole and Mahmoud, Amir},
title = {Abstract TH303: Uncontrolled Hypertension in a Young Adult With Thrombotic Microangiopathy: Cause, Consequence, or Both?},
journal = {Hypertension},
year = {2026},
volume = {83},
number = {Suppl_1},
doi = {10.1161/hyp.83.suppl_1.th303}
}
EUVIMED